<DOC>
	<DOCNO>NCT01209351</DOCNO>
	<brief_summary>The primary objective study assess effect 10 consecutive , daily , subcutaneous dos 4 mg teduglutide compare placebo gastric empty assess acetaminophen absorption kinetics healthy subject .</brief_summary>
	<brief_title>Effect Teduglutide Gastric Emptying Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Informed nature study agree able read , review , understand , sign inform consent document prior screen assessment complete . 2 . Completed screen process within 30 day prior check 3 . Adult male females age 18 45 year good health determine medical history , physical examination , ECG , laboratory test 4 . Women : ( 1 ) postmenopausal ; ( 2 ) surgically sterilize , OR ( 3 ) childbearing potential negative pregnancy test screen checkin consent use acceptable method contraception duration study four week follow last dose study drug . 1 . Allergy sensitivity acetaminophen 2 . History structural abnormality pathology GI tract diseases/conditions affect GI motility include follow : Gastric , small bowel colonic resection , Colon cancer GI Tract cancer Inflammatory bowel disease , Irritable bowel disease , Diabetes Mellitus , Gallstones cholecystectomy , Appendectomy , hernia repair , benign polypectomy exclude , History Gilbert 's Syndrome 3 History hepatitis pancreatitis 4 Evidence abnormal hepatobiliary laboratory parameter ( &gt; ULN serum ALT ; AST ; ALP ; GGT ; and/or total , direct indirect bilirubin ) 5 Serum amylase lipase upper limit normal 6 Body mass index ( BMI ) &gt; 30 kg/m2 7 Intention use medication potentially affect GI tract motility 8 History viral bacterial infection , allergy , inflammatory process surgery within 3 week checkin day . 9 Clinical evidence history ( include medical medication history , physical examination , laboratory , ECG available test result medical image study ) significant cardiovascular , respiratory , renal , gastrointestinal , hematologic ( eg , anemia ) , neurologic , psychiatric condition disease may interfere objective study subject successfully complete study 10 Presently take prescription counter medication include product contain acetaminophen , vitamin , herbs dietary supplement , discontinue . Prohibited medication must discontinue least 7 day prior checkin medication supplement must stop least 72 hour prior checkin . 11 Current recent history ( within 12 month ) drug alcohol abuse 12 Positive drug alcohol screen 13 Current recent history ( within 3 month ) use tobacco product 14 Positive urine cotinine screen 15 Abnormalities clinical chemistry , hematology , urinalysis laboratory variable 16 Positive result virology test acute chronic infectious human immunodeficiency virus ( HIV ) hepatitis virus infection 17 Pregnant lactating female ; positive beta human chorionic gonadotropin ( bhCG ) pregnancy test females 18 Special dietary requirement would preclude subject 's acceptance high fat high caloric , standardize meal 19 Blood donation within 4 week checkin day 20 Participation another clinical trial investigational drug device within last month ( single dose ) least 3 month ( multiple dose ) within 10 time halflife respective investigational drug , whatever longer , screen evaluation . For biologics minimum period least 6 month time duration pharmacodynamic effect 10 time halflife respective drug , whatever longer , screen evaluation . 21 Lack ability willingness give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>teduglutide</keyword>
</DOC>